SpyGlass Pharma, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
SpyGlass Pharma announced positive 4-year interim data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL) in 21 evaluable glaucoma patients. Key results: 37% mean IOP reduction (25.1→15.9 mmHg), 86% remained off topical drops, 90% maintained visual acuity, and zero product-related adverse events. The Phase 3 program targets 505(b)(2) NDA submission; trial follows patients through 2029.
Why this rating
Late-stage clinical validation of lead product with compelling durability data strengthens NDA pathway. Addresses $243M company's key milestone; meaningful de-risking before regulatory decision, but not yet approval.
Price action (we called it positive)
before filing · preread $24.60 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.